Avidity Partners 13F holdings, Q2 2022
Holdings as of June 30, 2022 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 82 US equity positions worth $4.4bn in its Q2 2022 13F filing. The largest position was AZN at 5.3% of the reported book, followed by VRTX and ARGX. Against the Q1 2022 filing, it opened 9 new positions, added to 29 and reduced 9 among the top 50 holdings.
What did Avidity Partners own in Q2 2022? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2022 |
|---|---|---|---|---|---|---|---|
| 1 | AZN ASTRAZENECA PLC | Healthcare | 5.3% | $231.2m | 3,499,000 | -5% | reduced |
| 2 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 5.1% | $223.5m | 793,000 | 45% | added |
| 3 | ARGX ARGENX SE | Healthcare | 5.0% | $216.9m | 572,500 | 225% | added |
| 4 | ELV ELEVANCE HEALTH INC | Healthcare | 4.9% | $212.8m | 441,000 | 10% | added |
| 5 | AVTR AVANTOR INC | Healthcare | 4.7% | $206.9m | 6,652,700 | 17% | added |
| 6 | LLY LILLY ELI & CO | Healthcare | 4.5% | $197.8m | 610,000 | – | new |
| 7 | HUM HUMANA INC | Healthcare | 4.4% | $193.0m | 412,300 | 107% | added |
| 8 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 3.9% | $171.0m | 725,600 | 1% | added |
| 9 | JNJ JOHNSON & JOHNSON | Healthcare | 3.7% | $159.8m | 900,200 | 154% | added |
| 10 | HORIZON THERAPEUTICS PUB L | 3.4% | $148.1m | 1,856,900 | 64% | added | |
| 11 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.3% | $143.1m | 1,467,600 | 27% | added |
| 12 | ARVN ARVINAS INC | Healthcare | 3.2% | $141.2m | 3,355,623 | 15% | added |
| 13 | XBI SPDR SER TR | 3.2% | $139.3m | 1,875,000 | 326% | added | |
| 14 | MCK MCKESSON CORP | Healthcare | 2.9% | $126.8m | 388,800 | 105% | added |
| 15 | UNH UNITEDHEALTH GROUP INC | Healthcare | 2.9% | $124.4m | 242,200 | -7% | reduced |
| 16 | ABBV ABBVIE INC | Healthcare | 2.7% | $115.6m | 755,000 | -49% | reduced |
| 17 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.4% | $104.9m | 5,450,000 | 13% | added |
| 18 | CATALENT INC | 2.4% | $102.5m | 955,000 | 22% | added | |
| 19 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 2.3% | $100.8m | 3,585,881 | 13% | added |
| 20 | SEAGEN INC | 2.2% | $97.3m | 550,000 | 450% | added | |
| 21 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 2.2% | $94.1m | 2,525,000 | 111% | added |
| 22 | BIIB BIOGEN INC | Healthcare | 2.1% | $89.8m | 440,566 | 21% | added |
| 23 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.0% | $88.3m | 1,479,500 | 70% | added |
| 24 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 1.6% | $70.0m | 1,035,000 | – | new |
| 25 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 1.3% | $58.2m | 1,125,194 | 188% | added |
| 26 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.3% | $55.0m | 1,000,000 | -9% | reduced |
| 27 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.2% | $50.7m | 1,438,999 | 51% | added |
| 28 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 1.2% | $50.4m | 1,350,000 | -1% | reduced |
| 29 | NTRA NATERA INC | Healthcare | 1.1% | $48.5m | 1,369,100 | 5% | added |
| 30 | INTRA-CELLULAR THERAPIES INC | 1.0% | $44.3m | 775,504 | – | new | |
| 31 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.9% | $41.0m | 2,972,947 | 11% | added |
| 32 | BELLUS HEALTH INC NEW | 0.9% | $39.4m | 4,265,000 | 16% | added | |
| 33 | ALT ALTIMMUNE INC | Healthcare | 0.8% | $34.9m | 2,981,000 | 4% | added |
| 34 | KEZAR LIFE SCIENCES INC | 0.8% | $33.5m | 4,050,000 | 15% | added | |
| 35 | AVIDITY BIOSCIENCES INC | 0.7% | $30.2m | 2,080,200 | 2% | added | |
| 36 | KARUNA THERAPEUTICS INC | 0.6% | $25.9m | 204,570 | – | new | |
| 37 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.6% | $25.8m | 1,325,000 | – | new |
| 38 | ARKG ARK ETF TR | 0.5% | $23.6m | 750,000 | – | new | |
| 39 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 0.4% | $19.3m | 758,211 | -3% | reduced |
| 40 | NKTX NKARTA INC | Healthcare | 0.4% | $17.4m | 1,414,082 | – | new |
| 41 | PHAT PHATHOM PHARMACEUTICALS INC | 0.4% | $16.2m | 1,919,800 | -1% | reduced | |
| 42 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 0.4% | $16.0m | 2,950,000 | 5% | added |
| 43 | DECIPHERA PHARMACEUTICALS IN | 0.4% | $15.8m | 1,200,000 | – | new | |
| 44 | NUVB NUVATION BIO INC | Healthcare | 0.4% | $15.7m | 4,855,000 | -0% | held |
| 45 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.4% | $15.4m | 1,392,300 | -77% | reduced |
| 46 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.3% | $13.7m | 450,000 | – | new |
| 47 | SIBN SI-BONE INC | Healthcare | 0.3% | $13.2m | 1,000,000 | 0% | held |
| 48 | SEASPINE HLDGS CORP | 0.3% | $11.4m | 2,010,000 | 0% | held | |
| 49 | ATEC ALPHATEC HLDGS INC | Healthcare | 0.3% | $11.2m | 1,715,000 | -37% | reduced |
| 50 | APELLIS PHARMACEUTICALS INC | 0.2% | $9.7m | 215,000 | 2% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.